Literature DB >> 16406554

Presence of anti-platelet IgM and IgG antibodies in dogs naturally infected by Leishmania infantum.

G Terrazzano1, L Cortese, D Piantedosi, S Zappacosta, A Di Loria, D Santoro, G Ruggiero, P Ciaramella.   

Abstract

Thirty-three dogs, naturally infected by Leishmania infantum, were enrolled in the study and were classified as oligo-symptomatic (n. 15) and symptomatic or markedly symptomatic (n. 18). A control group was 10 healthy dogs. A haematological profile was obtained and the dogs serum was employed to assess the presence of platelet binding IgM and IgG antibodies (PBIgM, PBIgG) using flow cytometry. FITC labelled goat anti-dog IgM or IgG were used to detect PBIgM and PBIgG. Samples with a mean fluorescence intensity (MFI) that was 100 channels higher on a log scale for more than 30% of the platelets than seen in negative control platelets from a healthy dog were considered positive for the presence of anti-platelet antibodies (PBIg). Twenty-one (63.3%) dogs revealed the presence of PBIg. Six of them were oligo-symptomatic while 15 showed moderate or severe clinical signs of illness. All the dogs with PBIg showed the presence of PBIgM, with nine animals showing both PBIgM and PBIgG. Nine of 18 symptomatic or markedly symptomatic dogs showed thrombocytopenia, while normal platelet counts were observed in all oligo-symptomatic animals. Eight of 9 thrombocytopenic animals showed the presence of PBIgM, while six of them showed PBIgG. One thrombocytopenic dog was negative for PBIg. This study is the first report documenting the presence of PBIg in natural canine leishmaniasis implying a pathogenic association between thrombocytopenia and the presence of antibody against platelet membrane.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16406554     DOI: 10.1016/j.vetimm.2005.11.001

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  7 in total

Review 1.  The immunopathology of canine vector-borne diseases.

Authors:  Michael J Day
Journal:  Parasit Vectors       Date:  2011-04-13       Impact factor: 3.876

2.  Clinical and immunopathological findings during long term follow-up in Leishmania infantum experimentally infected dogs.

Authors:  Melissa Moura Costa Abbehusen; Valter Dos Anjos Almeida; Manuela da S Solcà; Laís da Silva Pereira; Dirceu Joaquim Costa; Leonardo Gil-Santana; Patricia Torres Bozza; Deborah Bittencourt Moté Fraga; Patrícia Sampaio Tavares Veras; Washington Luis Conrado Dos-Santos; Bruno Bezerril Andrade; Claudia Ida Brodskyn
Journal:  Sci Rep       Date:  2017-11-21       Impact factor: 4.379

3.  Characteristics of hemostasis during experimental Ehrlichia canis infection.

Authors:  Sarah Shropshire; Christine Olver; Michael Lappin
Journal:  J Vet Intern Med       Date:  2018-04-27       Impact factor: 3.333

Review 4.  Platelet Function and Therapeutic Applications in Dogs: Current Status and Future Prospects.

Authors:  Laura Cortese; Pete W Christopherson; Alessandra Pelagalli
Journal:  Animals (Basel)       Date:  2020-01-25       Impact factor: 2.752

5.  Detection and dynamics of anti-platelet antibodies in thrombocytopenic dogs with and without idiopathic immune thrombocytopenia.

Authors:  Sarah Shropshire; Steven Dow; Michael Lappin
Journal:  J Vet Intern Med       Date:  2020-02-18       Impact factor: 3.333

6.  An immune-modulating diet increases the regulatory T cells and reduces T helper 1 inflammatory response in Leishmaniosis affected dogs treated with standard therapy.

Authors:  Laura Cortese; Mariangela Annunziatella; Anna Teresa Palatucci; Sarah Lanzilli; Valentina Rubino; Alessandro Di Cerbo; Sara Centenaro; Gianandrea Guidetti; Sergio Canello; Giuseppe Terrazzano
Journal:  BMC Vet Res       Date:  2015-12-03       Impact factor: 2.741

7.  Ehrlichia canis in dogs experimentally infected, treated, and then immune suppressed during the acute or subclinical phases.

Authors:  Masahiko Sato; Julia K Veir; Sarah B Shropshire; Michael R Lappin
Journal:  J Vet Intern Med       Date:  2020-04-08       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.